Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02500745
Other study ID # LAA velocity & LA volume
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 2, 2014
Last updated July 14, 2015
Start date July 2015
Est. completion date July 2017

Study information

Verified date July 2015
Source University of Cincinnati
Contact Elsayed Abo-salem
Phone 513-558-1032
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

After obtaining a consent, bed side cardiac ultrasonography will be performed for cases undergoing transesophageal echocardiography to evaluate the correlation between left atrium volume and left atrial appendage flow velocity which can predict the thrombosis risk.


Description:

Informed consent will be obtained prior to any research related procedures Prior to performing the transesophageal echocardiography, 4 and a 2-chamber transthoracic images will be obtained to perform standard left atrial volumetric assessment as well as speckle tracking interrogation. Both these procedures will be performed offline. The transesophageal echocardiography will be performed using available equipment with a 5- to 7-megaHertz multiplane transducer and according to standard of care. All images will be acquired per American Society of Echocardiography guidelines and will be recorded for further analysis. The left atrial appendage will be best visualized in the 60, 90 and 110 degree imaging planes and left atrial appendage contraction velocity will be recorded by placing a pulsed wave Doppler sample volume inside the proximal third of the left atrial appendage at each angle. In addition, images will be recorded using a 3-beat cycle capture to later perform offline velocity vector imaging analysis for left atrial appendage speckle tracking analysis. The transthoracic echocardiography will be performed just before the transesophageal echocardiography examination using a 2- to 4-megaHertz transducer and according to standard practice guidelines. The following echocardiographic variables will be prospectively measured and calculated: left ventricle ejection fraction using Simpson method, left atrial volume will be measured using biplane method and left atrium volume index is calculated based on body surface area. Tissue Doppler images of mitral valve annulus will be measured and Pulsed wave Doppler of mitral inflow velocity.

Study does not include follow up. Study duration is up to 24 months


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date July 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Study will include all patients 18-80 years of age and referred for transesophageal evaluation of left atrium or left atrium appendage for appropriate clinical indications, at the University of Cincinnati University Medical Center and VA Medical Center.

Exclusion Criteria:

- Patients with either moderate to sever mitral valve disease or previous prosthetic mitral replacement.

- Patients with acute heart failure

- History of previous left atrium appendage surgical intervention.

- Pregnant women

Study Design

Time Perspective: Cross-Sectional


Related Conditions & MeSH terms

  • Thrombosis of Left Atrial Appendage

Locations

Country Name City State
United States University of cincinnati medical center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between left atrium volume index and Left atrial appendage flow velocity Day 1 No
See also
  Status Clinical Trial Phase
Terminated NCT02256683 - Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Phase 2
Terminated NCT02039167 - Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease N/A